Modulating the pharmacokinetics of therapeutic antibodies
| Autor: | M. P. Deonarain, A. Constantinou, Chen Chen |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Drug
chemistry.chemical_classification biology Chemistry media_common.quotation_subject Serum albumin Bioengineering General Medicine Applied Microbiology and Biotechnology Fusion protein Antibodies law.invention Amino acid Biochemistry law PEGylation biology.protein Recombinant DNA Immunologic Factors Antibody Function (biology) Biotechnology media_common Half-Life |
| Zdroj: | Biotechnology letters. 32(5) |
| ISSN: | 1573-6776 |
| Popis: | With the advent of antibody fragments and alternative binding scaffolds, that are devoid of Fc-regions, strategies to increase the half-life of small proteins are becoming increasingly important. Currently, the established method is chemical PEGylation, but more elaborate approaches are being described such as polysialylation, amino acid polymers and albumin-binding derivatives. This article reviews the main strategies for pharmacokinetic enhancement, primarily chemical conjugates and recombinant fusions that increase apparent molecular weight or hydrodynamic radius or interact with serum albumin which itself has a long plasma half-life. We highlight the key chemical linkage methods that preserve antibody function and retain stability and look forward to the next generation of technologies which promise to make better quality pharmaceuticals with lower side effects. Although restricted to antibodies, all of the approaches covered can be applied to other biotherapeutics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink